Institute of Biostructure and Bioimaging, CNR and Department of Biological Sciences, University of Napoli 'Federico II', via Mezzocannone 16, 80134 Napoli, Italy
References: Carmeliet, P., Angiogenesis in health and disease (2003) Nat Med, 9, pp. 653-66
Hanahan, D., Folkman, J., Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis (1996) Cell, 86, pp. 353-364
Carmeliet, P., Jain, R.K., Angiogenesis in cancer and other diseases (2000) Nature, 407, pp. 249-257
Bergers, G., Benjamin, L.E., Tumorigenesis and the angiogenic switch (2003) Nat Rev Cancer, 3, pp. 401-410
Ruoslahti, E., Specialization of tumour vasculature (2002) Nat Rev Cancer, 2, pp. 83-90
Helisch, A., Schaper, W., Angiogenesis and arteriogenesis - Not yet for prescription (2000) Z Kardiol, 89, pp. 239-244
Simons, M., Ware, J.A., Therapeutic angiogenesis in cardiovascular disease (2003) Nat Rev Drug Discov, 2, pp. 863-871
Schaper, W., Ito, W.D., Molecular mechanisms of coronary collateral vessel growth (1996) Circ Res, 79, pp. 911-919
Schultz, A., Lavie, L., Hochberg, I., Beyar, R., Stone, T., Skorecki, K., Lavie, P., Levy, A.P., Interindividual heterogeneity in the hypoxic regulation of VEGF: Significance for the development of the coronary artery collateral circulation (1999) Circulation, 100, pp. 547-552
Isner, J.M., Tissue responses to ischemia: Local and remote responses for preserving perfusion of ischemic muscle (2000) J Clin Invest, 106, pp. 615-619
Featherstone, J., Griffiths, S., From the analyst's couch. Drugs that target angiogenesis (2002) Nat Rev Drug Discov, 1, pp. 413-414
Jain, R.K., Carmeliet, P.F., Vessels of death or life (2001) Sci Am, 285, pp. 38-45
Emanueli, C., Madeddu, P., Changing the logic of therapeutic angiogenesis for ischemic disease (2005) Trends Mol Med, 11, pp. 207-216
Lee, C.G., Link, H., Baluk, P., Homer, R.J., Chapoval, S., Bhandari, V., Kang, M.J., Elias, J.A., Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung (2004) Nat Med, 10, pp. 1095-1103
Cristofanilli, M., Charnsangavej, C., Hortobagyi, G.N., Angiogenesis modulation in cancer research: Novel clinical approaches (2002) Nat Rev Drug Discov, 1, pp. 415-426
Bouma-Ter Steege, J.C.A., Mayo, K.H., Griffioen, A.W., Angiostatic proteins and peptides (2001) Crit Rev Eukaryot Gene Expr, 11, pp. 319-334
Oku, N., Asai, T., Watanabe, K., Kuromi, K., Nagatsuka, M., Kurohane, K., Kikkawa, H., Taki, T., Anti-neovascular therapy using novel peptides homing to angiogenic vessels (2002) Oncogene, 21, pp. 2662-2669
Asai, T., Nagatsuka, M., Kuromi, K., Yamakawa, S., Kurohane, K., Ogino, K., Tanaka, M., Oku, N., Suppression of tumor growth by novel peptides homing to tumor-derived new blood vessels (2002) FEBS Lett, 510, pp. 206-210
Mayo, K.H., Dings, R.P., Flader, C., Nesmelova, I., Hargittai, B., Van Der Schaft, D.W., Van Eijk, L.I., Griffioen, A.W., Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity (2003) J Biol Chem, 278, pp. 45746-45752
Blaskovich, M.A., Lin, Q., Delarue, F.L., Sun, J., Park, H.S., Coppola, D., Hamilton, A.D., Sebti, S.M., Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice (2000) Nat Biotechnol, 18, pp. 1065-1070
Koivunen, E., Arap, W., Valtanen, H., Rainisalo, A., Medina, O.P., Heikkila, P., Kantor, C., Pasqualini, R., Tumor targeting with a selective gelatinase inhibitor (1999) Nat Biotechnol, 17, pp. 768-774
Li, J., Post, M., Volk, R., Gao, Y., Li, M., Metais, C., Sato, K., Simons, M., PR39, a peptide regulator of angiogenesis (2000) Nat Med, 6, pp. 49-55
Hamada, Y., Nokihara, K., Okazaki, M., Fujitani, W., Matsumoto, T., Matsuo, M., Umakoshi, Y., Matsuura, N., Angiogenic activity of osteopontin-derived peptide SVVYGLR (2003) Biochem Biophys Res Commun, 310, pp. 153-157
Ferrara, N., VEGF: An update on biological and therapeutic aspects (2000) Curr Opin Biotechnol, 11, pp. 617-624
Ferrara, N., Gerber, H.P., Lecouter, J., The biology of VEGF and its receptors (2003) Nat Med, 9, pp. 669-676
Ferrara, N., Davis-Smyth, T., The biology of vascular endothelial growth factor (1997) Endocr Rev, 18, pp. 4-25
Autiero, M., Waltenberger, J., Communi, D., Kranz, A., Moons, L., Lambrechts, D., Kroll, J., Mayr-Beyrle, U., Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 (2003) Nat Med, 9, pp. 936-943
Brogi, E., Schatteman, G., Wu, T., Kim, E.A., Varticovski, L., Keyt, B., Isner, J.M., Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression (1996) J Clin Invest, 97, pp. 469-476
Abedi, H., Zachary, I., Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells (1997) J Biol Chem, 272, pp. 15442-15451
Muller, Y.A., Li, B., Christinger, H.W., Wells, J.A., Cunningham, B.C., De Vos, A.M., Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site (1997) Proc Natl Acad Sci U S a, 94, pp. 7192-7197
Muller, Y.A., Christinger, H.W., Keyt, B.A., De Vos, A.M., The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 a resolution: Multiple copy flexibility and receptor binding (1997) Structure, 5, pp. 1325-1338
Wiesmann, C., Christinger, H.W., Cochran, A.G., Cunningham, B.C., Fairbrother, W.J., Keenan, C.J., Meng, G., De Vos, A.M., Crystal structure of the complex between VEGF and a receptor-blocking peptide (1998) Biochemistry, 37, pp. 17765-17772
Pan, B., Li, B., Russell, S.J., Tom, J.Y., Cochran, A.G., Fairbrother, W.J., Solution structure of a phage-derived peptide antagonist in complex with vascular endothelial growth factor (2002) J Mol Biol, 316, pp. 769-787
Muller, Y.A., Chen, Y., Christinger, H.W., Li, B., Cunningham, B.C., Lowman, H.B., De Vos, A.M., VEGF and the Fab fragment of a humanized neutralizing antibody: Crystal structure of the complex at 2.4 a resolution and mutational analysis of the interface (1998) Structure, 6, pp. 1153-1167
Wiesmann, C., Fuh, G., Christinger, H.W., Eigenbrot, C., Wells, J.A., De Vos, A.M., Crystal structure at 1.7 a resolution of VEGF in complex with domain 2 of the Flt-1 receptor (1997) Cell, 91, pp. 695-704
Keyt, B.A., Nguyen, H.V., Berleau, L.T., Duarte, C.M., Park, J., Chen, H., Ferrara, N., Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis (1996) J Biol Chem, 271, pp. 5638-5646
Ferrara, N., Hillan, K.J., Gerber, H.P., Novotny, W., Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer (2004) Nat Rev Drug Discov, 3, pp. 391-400
Cooke, S.P., Boxer, G.M., Lawrence, L., Pedley, R.B., Spencer, D.I., Begent, R.H., Chester, K.A., A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: Receptor complex (2001) Cancer Res, 61, pp. 3653-3659
Lu, D., Shen, J., Vil, M.D., Zhang, H., Jimenez, X., Bohlen, P., Witte, L., Zhu, Z., Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity (2003) J Biol Chem, 278, pp. 43496-43507
Prewett, M., Huber, J., Li, Y., Santiago, A., O'Connor, W., King, K., Overholser, J., Hicklin, D.J., Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors (1999) Cancer Res, 59, pp. 5209-5218
Willett, C.G., Boucher, Y., Di Tomaso, E., Duda, D.G., Munn, L.L., Tong, R.T., Chung, D.C., Fischman, A.J., Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (2004) Nat Med, 10, pp. 145-147
Underiner, T.L., Ruggeri, B., Gingrich, D.E., Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy (2004) Curr Med Chem, 11, pp. 731-745
Sun, J., Wang, D.A., Jain, R.K., Carie, A., Paquette, S., Ennis, E., Blaskovich, M.A., Sebti, S.M., Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors (2005) Oncogene, 24, pp. 4701-4709
Sun, J., Blaskovich, M.A., Jain, R.K., Delarue, F., Paris, D., Brem, S., Wotoczek-Obadia, M., Sebti, S.M., Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor (2004) Cancer Res, 64, pp. 3586-3592
Holash, J., Davis, S., Papadopoulos, N., Croll, S.D., Ho, L., Russell, M., Boland, P., Fandl, J.P., VEGF-Trap: A VEGF blocker with potent antitumor effects (2002) Proc Natl Acad Sci U S a, 99, pp. 11393-11398
Kim, E.S., Serur, A., Huang, J., Manley, C.A., McCrudden, K.W., Frischer, J.S., Soffer, S.Z., Yamashiro, D.J., Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma (2002) Proc Natl Acad Sci U S a, 99, pp. 11399-11404
Takei, Y., Kadomatsu, K., Yuzawa, Y., Matsuo, S., Muramatsu, T., A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics (2004) Cancer Res, 64, pp. 3365-3370
Niethammer, A.G., Xiang, R., Becker, J.C., Wodrich, H., Pertl, U., Karsten, G., Eliceiri, B.P., Reisfeld, R.A., A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth (2002) Nat Med, 8, pp. 1369-1375
Fairbrother, W.J., Christinger, H.W., Cochran, A.G., Fuh, G., Keenan, C.J., Quan, C., Shriver, S.K., Cunningham, B.C., Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site (1998) Biochemistry, 37, pp. 17754-17764
Binetruy-Tournaire, R., Demangel, C., Malavaud, B., Vassy, R., Rouyre, S., Kraemer, M., Plouet, J., Mazie, J.C., Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis (2000) EMBO J, 19, pp. 1525-1533
El-Mousawi, M., Tchistiakova, L., Yurchenko, L., Pietrzynski, G., Moreno, M., Stanimirovic, D., Ahmad, D., Alakhov, V., A vascular endothelial growth factor high affinity receptor 1-specific peptide with antiangiogenic activity identified using a phage display peptide library (2003) J Biol Chem, 278, pp. 46681-46691
Hetian, L., Ping, A., Shumei, S., Xiaoying, L., Luowen, H., Jian, W., Lin, M., Chengchao, S., A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor (2002) J Biol Chem, 277, pp. 43137-43142
An, P., Lei, H., Zhang, J., Song, S., He, L., Jin, G., Liu, X., Shou, C., Suppression of tumor growth and metastasis by a VEGFR-1 antagonizing peptide identified from a phage display library (2004) Int J Cancer, 111, pp. 165-173
Zilberberg, L., Shinkaruk, S., Lequin, O., Rousseau, B., Hagedorn, M., Costa, F., Caronzolo, D., Bello, L., Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor (2003) J Biol Chem, 278, pp. 35564-35573
Bae, D.G., Gho, Y.S., Yoon, W.H., Chae, C.B., Arginine-rich anti-vascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis (2000) J Biol Chem, 275, pp. 13588-13596
Jia, H., Jezequel, S., Lohr, M., Shaikh, S., Davis, D., Soker, S., Selwood, D., Zachary, I., Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF (2001) Biochem Biophys Res Commun, 283, pp. 164-173
Piossek, C., Schneider-Mergener, J., Schirner, M., Vakalopoulou, E., Germeroth, L., Thierauch, K.H., Vascular endothelial growth factor (VEGF) receptor II-derived peptides inhibit VEGF (1999) J Biol Chem, 274, pp. 5612-5619
Albini, A., Soldi, R., Giunciuglio, D., Giraudo, E., Benelli, R., Primo, L., Noonan, D., Bussolino, F., The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells (1996) Nat Med, 2, pp. 1371-1375
D'Andrea, L.D., Iaccarino, G., Fattorusso, R., Sorriento, D., Carannante, C., Capasso, D., Trimarco, B., Pedone, C., Targeting angiogenesis: Structural characterization and biological properties of a de novo engineered VEGF mimicking peptide (2005) Proc Natl Acad Sci U S a, 102, pp. 14215-14220
Giancotti, F.G., Ruoslahti, E., Integrin signaling (1999) Science, 285, pp. 1028-1032
Van Der Flier, A., Sonnenberg, A., Function and interactions of integrins (2001) Cell Tissue Res, 305, pp. 285-298
Brooks, P.C., Clark, R.A., Cheresh, D.A., Requirement of vascular integrin alpha v beta 3 for angiogenesis (1994) Science, 264, pp. 569-571
Schlaepfer, D.D., Hauck, C.R., Sieg, D.J., Signaling through focal adhesion kinase (1999) Prog Biophys Mol Biol, 71, pp. 435-478
Longhurst, C.M., Jennings, L.K., Integrin-mediated signal transduction (1998) Cell Mol Life Sci, 54, pp. 514-526
Stupack, D.G., Puente, X.S., Boutsaboualoy, S., Storgard, C.M., Cheresh, D.A., Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins (2001) J Cell Biol, 155, pp. 459-470
Xiong, J.P., Stehle, T., Diefenbach, B., Zhang, R., Dunker, R., Scott, D.L., Joachimiak, A., Arnaout, M.A., Crystal structure of the extracellular segment of integrin alpha Vbeta3 (2001) Science, 294, pp. 339-345
Gottschalk, K.E., Gunther, R., Kessler, H., A three-state mechanism of integrin activation and signal transduction for integrin alpha(v)beta(3) (2002) Chembiochem, 3, pp. 470-473
Pierschbacher, M.D., Ruoslahti, E., Variants of the cell recognition site of fibronectin that retain attachment-promoting activity (1984) Proc Natl Acad Sci U S a, 81, pp. 5985-5988
Ruoslahti, E., Pierschbacher, M.D., New perspectives in cell adhesion: RGD and integrins (1987) Science, 238, pp. 491-497
Albelda, S.M., Buck, C.A., Integrins and other cell adhesion molecules (1990) FASEB J, 4, pp. 2868-2880
Humphries, M.J., The molecular basis and specificity of integrin-ligand interactions (1990) J Cell Sci, 97 (4), pp. 585-592
Hautanen, A., Gailit, J., Mann, D.M., Ruoslahti, E., Effects of modifications of the RGD sequence and its context on recognition by the fibronectin receptor (1989) J Biol Chem, 264, pp. 1437-1442
Miller, W.H., Keenan, R.M., Willette, R.N., Lark, M.W., Identification and in vivo efficacy of small-molecule antagonists of integrin alphavbeta3 (the vitronectin receptor) (2000) Drug Discov Today, 5, pp. 397-408
Marugan, J.J., Manthey, C., Anaclerio, B., Lafrance, L., Lu, T., Markotan, T., Leonard, K.A., Tomczuk, B., Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core (2005) J Med Chem, 48, pp. 926-934
Goodman, S.L., Holzemann, G., Sulyok, G.A., Kessler, H., Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins (2002) J Med Chem, 45, pp. 1045-1051
Haubner, R., Gratias, R., Diefenbach, B., Goodman, S., Joachimiak, A., Kessler, H., Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin alphaVbeta3 antagonists (1996) J Am Chem Soc, 118, pp. 7461-7472
Mitjans, F., Meyer, T., Fittschen, C., Goodman, S., Jonczyk, A., Marshall, J.F., Reyes, G., Piulats, J., In vivo therapy of malignant melanoma by means of antagonists of alphav integrins (2000) Int J Cancer, 87, pp. 716-723
Dechantsreiter, M.A., Planker, E., Matha, B., Lohof, E., Holzemann, G., Jonczyk, A., Goodman, S.L., Kessler, H., N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists (1999) J Med Chem, 42, pp. 3033-3040
Sulyok, G.A., Gibson, C., Goodman, S.L., Holzemann, G., Wiesner, M., Kessler, H., Solid-phase synthesis of a nonpeptide RGD mimetic library: New selective alphavbeta3 integrin antagonists (2001) J Med Chem, 44, pp. 1938-1950
Belvisi, L., Bernardi, A., Checchia, A., Manzoni, L., Potenza, D., Scolastico, C., Castorina, M., Pisano, C., Potent integrin antagonists from a small library of RGD-including cyclic pseudopeptides (2001) Org Lett, 3, pp. 1001-1004
Posey, J.A., Khazaeli, M.B., Delgrosso, A., Saleh, M.N., Lin, C.Y., Huse, W., Lobuglio, A.F., A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer (2001) Cancer Biother Radiopharm, 16, pp. 125-132
Kessler, H., Peptide conformations: Part 16. Solid-state carbon-13 NMR spectra of cyclotriprolines (1982) Angew Chem Int Ed Engl, 94, pp. 509-520
Aumailley, M., Gurrath, M., Muller, G., Calvete, J., Timpl, R., Kessler, H., Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1 (1991) FEBS Lett, 291, pp. 50-54
Pfaff, M., Tangemann, K., Muller, B., Gurrath, M., Muller, G., Kessler, H., Timpl, R., Engel, J., Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins (1994) J Biol Chem, 269, pp. 20233-20238
Haubner, R., Schmitt, W., Holzemann, G., Goodman, S., Jonczyk, A., Kessler, H., Cyclic RGD peptides containing beta-turn mimetics (1996) J Am Chem Soc, 118, pp. 7881-7891
Haubner, R., Finsinger, D., Kessler, H., Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the avb3 integrin for a new cancer therapy (1997) Angew Chem Int Ed Engl, 36, pp. 1374-1389
Kawaguchi, M., Hosotani, R., Ohishi, S., Fujii, N., Tulachan, S.S., Koizumi, M., Toyoda, E., Imamura, M., A novel synthetic Arg-Gly-Asp-containing peptide cyclo(-RGDf = V-) is the potent inhibitor of angiogenesis (2001) Biochem Biophys Res Commun, 288, pp. 711-717
Coleman, P.J., Brashear, K.M., Hunt, C.A., Hoffman, W.F., Hutchinson, J.H., Breslin, M.J., McVean, C.A., Ma, B., Non-peptide alpha(v)beta(3) antagonists. identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacements (2002) Bioorg Med Chem Lett, 3, pp. 31-34
Kumar, C.C., Malkowski, M., Yin, Z., Tanghetti, E., Yaremko, B., Nechuta, T., Varner, J., Armstrong, L., Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist (2001) Cancer Res, 61, pp. 2232-2238
Urbahns, K., Harter, M., Albers, M., Schmidt, D., Stelte-Ludwig, B., Bruggemeier, U., Vaupel, A., Gerdes, C., Biphenyls as potent vitronectin receptor antagonists (2002) Bioorg Med Chem Lett, 12, pp. 205-208
Van Well, R.M., Overkleeft, H.S., Van Der Marel, G.A., Bruss, D., Thibault, G., De Groot, P.G., Van Boom, J.H., Overhand, M., Solid-phase synthesis of cyclic RGD-furanoid sugar amino acid peptides as integrin inhibitors (2003) Bioorg Med Chem Lett, 13, pp. 331-334
Manthey, C., Lee, Y., Wang, A., Crysler, C., Zhao, S., Bone, R.F., Tomczuk, B.E., Characterization of O-guanidines as novel alphaVbeta3 inhibitors (2001) Proc Am Assoc Cancer Res, 42, p. 368
Marugan, J.J., Haslow, K.D., Crysler, C., Design, synthesis, and biochemical evaluation of novel alpha V beta 3 integrin ligands (2004) Bioorg Med Chem Lett, 14, pp. 4553-4555
Eskens, F.A., Dumez, H., Hoekstra, R., Perschl, A., Brindley, C., Bottcher, S., Wynendaele, W., Van Oosterom, A.T., Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours (2003) Eur J Cancer, 39, pp. 917-926
Pasqualini, R., Koivunen, E., Ruoslahti, E., Alpha v integrins as receptors for tumor targeting by circulating ligands (1997) Nat Biotechnol, 15, pp. 542-546
Gante, J., Peptidomimetics - Tailored enzyme inhibitors (1994) Angew Chem Int Ed Engl, 33, pp. 1699-1720
Gante, J., Azapeptides (1989) Synthesis, pp. 405-413
Gould, R.J., Polokoff, M.A., Friedman, P.A., Huang, T.F., Holt, J.C., Cook, J.J., Niewiarowski, S., Disintegrins: A family of integrin inhibitory proteins from viper venoms (1990) Proc Soc Exp Biol Med, 195, pp. 168-171
Niewiarowski, S., McLane, M.A., Kloczewiak, M., Stewart, G.J., Disintegrins and other naturally occurring antagonists of platelet fibrinogen receptors (1994) Semin Hematol, 31, pp. 289-300
Gan, Z.R., Gould, R.J., Jacobs, J.W., Friedman, P.A., Polokoff, M.A., Echistatin. a potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus (1988) J Biol Chem, 263, pp. 19827-19832
Marcinkiewicz, C., Rosenthal, L.A., Mosser, D.M., Kunicki, T.J., Niewiarowski, S., Immunological characterization of eristostatin and echistatin binding sites on alpha IIb beta 3 and alpha V beta 3 integrins (1996) Biochem J, 317 (3), pp. 817-825
Zartler, E.R., Shapiro, M.J., Fragonomics: Fragment-based drug discovery (2005) Curr Opin Chem Biol, 9, pp. 366-370
Yamada, K.M., Even-Ram, S., Integrin regulation of growth factor receptors (2002) Nat Cell Biol, 4, pp. E75-E76
Brooks, P.C., Stromblad, S., Sanders, L.C., Von Schalscha, T.L., Aimes, R.T., Stetler-Stevenson, W.G., Quigley, J.P., Cheresh, D.A., Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3 (1996) Cell, 85, pp. 683-693
De, S., Razorenova, O., McCabe, N.P., O'Toole, T., Qin, J., Byzova, T.V., VEGF-integrin interplay controls tumor growth and vascularization (2005) Proc Natl Acad Sci U S a, 102, pp. 7589-7594
Mizukami, Y., Jo, W.S., Duerr, E.M., Gala, M., Li, J., Zhang, X., Zimmer, M.A., Chung, D.C., Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells (2005) Nat Med, 11, pp. 992-997
Carmeliet, P., VEGF gene therapy: Stimulating angiogenesis or angiomagenesis (2000) Nat Med, 6, pp. 1102-1103
Weis, S.M., Cheresh, D.A., Pathophysiological consequences of VEGF-induced vascular permeability (2005) Nature, 437, pp. 497-504
Liu, S., Edwards, D.S., 99mTc-labeled small peptides as diagnostic radiopharmaceuticals (1999) Chem Rev, 99, pp. 2235-2268
Li, S., Peck-Radosavljevic, M., Kienast, O., Preitfellner, J., Hamilton, G., Kurtaran, A., Pirich, C., Dudczak, R., Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy (2003) Ann Oncol, 14, pp. 1274-1277
Haubner, R., Wester, H.J., Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies (2004) Curr Pharm des, 10, pp. 1439-1455
Miller, J.C., Pien, H.H., Sahani, D., Sorensen, A.G., Thrall, J.H., Imaging angiogenesis: Applications and potential for drug development (2005) J Natl Cancer Inst, 97, pp. 172-187
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., Holash, J., Vascular-specific growth factors and blood vessel formation (2000) Nature, 407, pp. 242-248
Isner, J. M., Tissue responses to ischemia: Local and remote responses for preserving perfusion of ischemic muscle (2000) J Clin Invest, 106, pp. 615-619
Jain, R. K., Carmeliet, P. F., Vessels of death or life (2001) Sci Am, 285, pp. 38-45
Lee, C. G., Link, H., Baluk, P., Homer, R. J., Chapoval, S., Bhandari, V., Kang, M. J., Elias, J. A., Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung (2004) Nat Med, 10, pp. 1095-1103
Tozer, G. M., Kanthou, C., Baguley, B. C., Disrupting tumour blood vessels (2005) Nat Rev Cancer, 5, pp. 423-435
Mayo, K. H., Dings, R. P., Flader, C., Nesmelova, I., Hargittai, B., Van Der Schaft, D. W., Van Eijk, L. I., Griffioen, A. W., Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity (2003) J Biol Chem, 278, pp. 45746-45752
Blaskovich, M. A., Lin, Q., Delarue, F. L., Sun, J., Park, H. S., Coppola, D., Hamilton, A. D., Sebti, S. M., Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice (2000) Nat Biotechnol, 18, pp. 1065-1070
Muller, Y. A., Li, B., Christinger, H. W., Wells, J. A., Cunningham, B. C., De Vos, A. M., Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site (1997) Proc Natl Acad Sci U S a, 94, pp. 7192-7197
Muller, Y. A., Christinger, H. W., Keyt, B. A., De Vos, A. M., The crystal structure of vascular endothelial growth factor (VEGF) refined to 1. 93 a resolution: Multiple copy flexibility and receptor binding (1997) Structure, 5, pp. 1325-1338
Muller, Y. A., Chen, Y., Christinger, H. W., Li, B., Cunningham, B. C., Lowman, H. B., De Vos, A. M., VEGF and the Fab fragment of a humanized neutralizing antibody: Crystal structure of the complex at 2. 4 a resolution and mutational analysis of the interface (1998) Structure, 6, pp. 1153-1167
Keyt, B. A., Nguyen, H. V., Berleau, L. T., Duarte, C. M., Park, J., Chen, H., Ferrara, N., Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis (1996) J Biol Chem, 271, pp. 5638-5646
Cooke, S. P., Boxer, G. M., Lawrence, L., Pedley, R. B., Spencer, D. I., Begent, R. H., Chester, K. A., A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: Receptor complex (2001) Cancer Res, 61, pp. 3653-3659
Willett, C. G., Boucher, Y., Di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Fischman, A. J., Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (2004) Nat Med, 10, pp. 145-147
Underiner, T. L., Ruggeri, B., Gingrich, D. E., Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy (2004) Curr Med Chem, 11, pp. 731-745
Sun, J., Wang, D. A., Jain, R. K., Carie, A., Paquette, S., Ennis, E., Blaskovich, M. A., Sebti, S. M., Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors (2005) Oncogene, 24, pp. 4701-4709
Kim, E. S., Serur, A., Huang, J., Manley, C. A., McCrudden, K. W., Frischer, J. S., Soffer, S. Z., Yamashiro, D. J., Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma (2002) Proc Natl Acad Sci U S a, 99, pp. 11399-11404
Niethammer, A. G., Xiang, R., Becker, J. C., Wodrich, H., Pertl, U., Karsten, G., Eliceiri, B. P., Reisfeld, R. A., A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth (2002) Nat Med, 8, pp. 1369-1375
Bae, D. G., Gho, Y. S., Yoon, W. H., Chae, C. B., Arginine-rich anti-vascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis (2000) J Biol Chem, 275, pp. 13588-13596
D'Andrea, L. D., Iaccarino, G., Fattorusso, R., Sorriento, D., Carannante, C., Capasso, D., Trimarco, B., Pedone, C., Targeting angiogenesis: Structural characterization and biological properties of a de novo engineered VEGF mimicking peptide (2005) Proc Natl Acad Sci U S a, 102, pp. 14215-14220
Giancotti, F. G., Ruoslahti, E., Integrin signaling (1999) Science, 285, pp. 1028-1032
Brooks, P. C., Clark, R. A., Cheresh, D. A., Requirement of vascular integrin alpha v beta 3 for angiogenesis (1994) Science, 264, pp. 569-571
Schlaepfer, D. D., Hauck, C. R., Sieg, D. J., Signaling through focal adhesion kinase (1999) Prog Biophys Mol Biol, 71, pp. 435-478
Longhurst, C. M., Jennings, L. K., Integrin-mediated signal transduction (1998) Cell Mol Life Sci, 54, pp. 514-526
Stupack, D. G., Puente, X. S., Boutsaboualoy, S., Storgard, C. M., Cheresh, D. A., Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins (2001) J Cell Biol, 155, pp. 459-470
Xiong, J. P., Stehle, T., Diefenbach, B., Zhang, R., Dunker, R., Scott, D. L., Joachimiak, A., Arnaout, M. A., Crystal structure of the extracellular segment of integrin alpha Vbeta3 (2001) Science, 294, pp. 339-345
Gottschalk, K. E., Gunther, R., Kessler, H., A three-state mechanism of integrin activation and signal transduction for integrin alpha (v) beta (3) (2002) Chembiochem, 3, pp. 470-473
Pierschbacher, M. D., Ruoslahti, E., Variants of the cell recognition site of fibronectin that retain attachment-promoting activity (1984) Proc Natl Acad Sci U S a, 81, pp. 5985-5988
Albelda, S. M., Buck, C. A., Integrins and other cell adhesion molecules (1990) FASEB J, 4, pp. 2868-2880
Humphries, M. J., The molecular basis and specificity of integrin-ligand interactions (1990) J Cell Sci, 97 (4), pp. 585-592
Miller, W. H., Keenan, R. M., Willette, R. N., Lark, M. W., Identification and in vivo efficacy of small-molecule antagonists of integrin alphavbeta3 (the vitronectin receptor) (2000) Drug Discov Today, 5, pp. 397-408
Marugan, J. J., Manthey, C., Anaclerio, B., Lafrance, L., Lu, T., Markotan, T., Leonard, K. A., Tomczuk, B., Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core (2005) J Med Chem, 48, pp. 926-934
Goodman, S. L., Holzemann, G., Sulyok, G. A., Kessler, H., Nanomolar small molecule inhibitors for alphav (beta) 6, alphav (beta) 5, and alphav (beta) 3 integrins (2002) J Med Chem, 45, pp. 1045-1051
Dechantsreiter, M. A., Planker, E., Matha, B., Lohof, E., Holzemann, G., Jonczyk, A., Goodman, S. L., Kessler, H., N-Methylated cyclic RGD peptides as highly active and selective alpha (V) beta (3) integrin antagonists (1999) J Med Chem, 42, pp. 3033-3040
Sulyok, G. A., Gibson, C., Goodman, S. L., Holzemann, G., Wiesner, M., Kessler, H., Solid-phase synthesis of a nonpeptide RGD mimetic library: New selective alphavbeta3 integrin antagonists (2001) J Med Chem, 44, pp. 1938-1950
Posey, J. A., Khazaeli, M. B., Delgrosso, A., Saleh, M. N., Lin, C. Y., Huse, W., Lobuglio, A. F., A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer (2001) Cancer Biother Radiopharm, 16, pp. 125-132
Coleman, P. J., Brashear, K. M., Hunt, C. A., Hoffman, W. F., Hutchinson, J. H., Breslin, M. J., McVean, C. A., Ma, B., Non-peptide alpha (v) beta (3) antagonists. identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacements (2002) Bioorg Med Chem Lett, 3, pp. 31-34
Kumar, C. C., Malkowski, M., Yin, Z., Tanghetti, E., Yaremko, B., Nechuta, T., Varner, J., Armstrong, L., Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha (v) beta3 and alpha (v) beta5 integrin receptor antagonist (2001) Cancer Res, 61, pp. 2232-2238
Van Well, R. M., Overkleeft, H. S., Van Der Marel, G. A., Bruss, D., Thibault, G., De Groot, P. G., Van Boom, J. H., Overhand, M., Solid-phase synthesis of cyclic RGD-furanoid sugar amino acid peptides as integrin inhibitors (2003) Bioorg Med Chem Lett, 13, pp. 331-334
Marugan, J. J., Haslow, K. D., Crysler, C., Design, synthesis, and biochemical evaluation of novel alpha V beta 3 integrin ligands (2004) Bioorg Med Chem Lett, 14, pp. 4553-4555
Eskens, F. A., Dumez, H., Hoekstra, R., Perschl, A., Brindley, C., Bottcher, S., Wynendaele, W., Van Oosterom, A. T., Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours (2003) Eur J Cancer, 39, pp. 917-926
Gould, R. J., Polokoff, M. A., Friedman, P. A., Huang, T. F., Holt, J. C., Cook, J. J., Niewiarowski, S., Disintegrins: A family of integrin inhibitory proteins from viper venoms (1990) Proc Soc Exp Biol Med, 195, pp. 168-171
Gan, Z. R., Gould, R. J., Jacobs, J. W., Friedman, P. A., Polokoff, M. A., Echistatin. a potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus (1988) J Biol Chem, 263, pp. 19827-19832
Zartler, E. R., Shapiro, M. J., Fragonomics: Fragment-based drug discovery (2005) Curr Opin Chem Biol, 9, pp. 366-370
Yamada, K. M., Even-Ram, S., Integrin regulation of growth factor receptors (2002) Nat Cell Biol, 4, pp. E75-E76
Brooks, P. C., Stromblad, S., Sanders, L. C., Von Schalscha, T. L., Aimes, R. T., Stetler-Stevenson, W. G., Quigley, J. P., Cheresh, D. A., Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3 (1996) Cell, 85, pp. 683-693
Weis, S. M., Cheresh, D. A., Pathophysiological consequences of VEGF-induced vascular permeability (2005) Nature, 437, pp. 497-504
Miller, J. C., Pien, H. H., Sahani, D., Sorensen, A. G., Thrall, J. H., Imaging angiogenesis: Applications and potential for drug development (2005) J Natl Cancer Inst, 97, pp. 172-187
Bogdanovich S, Kim Y, Mizutani T, Yasuma R, Tudisco L, Cicatiello V, Bastos-carvalho A, Kerur N, Hirano Y, Baffi JZ, Tarallo V, Li S, Yasuma T, Arpitha P, Fowler BJ, Wright CB, Apicella I, Greco A, Brunetti A, Ruvo M, Sandomenico A, Nozaki M, Ijima R, Kaneko H, Ogura Y, Terasaki H, Ambati BK, Leusen JH, Langdon WY, Clark MR, Armour KL, Bruhns P, Verbeek JS, Gelfand BD, De Falco S, Ambati J * Human IgG1 antibodies suppress angiogenesis in a target-independent manner(557 views) Signal Transduct Target Ther (ISSN: 2059-3635print), 2016; 1: N/D-N/D. Impact Factor:0 ViewExport to BibTeXExport to EndNote
Santulli G, Cipolletta E, Sorriento D, Del Giudice C, Anastasio A, Monaco S, Maione AS, Condorelli G, Puca A, Trimarco B, Illario M, Iaccarino G * CaMK4 gene deletion induces hypertension(349 views) J Am Heart Assoc Journal Of The American Heart Association (ISSN: 2047-9980), 2012; 1(4): N/D-N/D. Impact Factor:2.882 ViewExport to BibTeXExport to EndNote
Ntziachristos V, Cuénod CA, Fournier L, Balvay D, Pradel C, Siauve N, Clement O, Jouannot E, Lucidarme O, Vecchio SD, Salvatore M, Law B, Tung C-H, Jain RK, Fukumura D, Munn LL, Brown EB, Schellenberger E, Montet X, Weissleder R, Clerck ND, Postnov A * Tumor Imaging(350 views) Textbook Of In Vivo Imaging In Vertebrates (ISSN: 9780-4700), 2007 Jul 16; 1: 277-309. Impact Factor:1.148 ViewExport to BibTeXExport to EndNote